Abstract
OBJECTIVE
Mitotane is an adrenocytolytic agent used in adrenocortical carcinoma, inducing adrenal insufficiency, requiring replacement treatment. Such therapy is not easy to monitor because of mitotane interference. Salivary cortisol reflects a free fraction of plasma cortisol and may be useful in such patients.
DESIGN
The aim of our study was to evaluate salivary cortisol by HPLC coupled to tandem-mass spectrometry (LC-MS/MS) and by an electrochemi-luminescence immunoassay (ECLIA) in patients treated with mitotane. We enrolled 6 patients receiving mitotane and 2 Addison disease patients as negative controls and determined salivary cortisol rhythm. We also determined the salivary cortisol rhythm in 8 healthy subjects. Salivary samples (n=112) were assayed by ECLIA, using Roche Modular E170, and by LC-MS/MS.
RESULTS
The mean values obtained by ECLIA were significantly higher than those obtained by LC-MS/MS in the mitotane group (p<0.001). In fact, in the group measured by LC-MS/ MS, we observed several peaks eluting at a retention time different from the cortisol group, presumably due to cortisol-like analogues. In Addison disease, since steroidogenesis is absent, salivary cortisol values measured by the two methods did not show any significant difference (p=0.61).
CONCLUSIONS
Salivary cortisol measured by LC-MS/MS is a selective method, excluding cortisol analogues accumulating in treated patients. Therefore, LC-MS/MS offers an effective system to monitor replacement therapy in mitotane treated patients.
Article PDF
Similar content being viewed by others
References
Schteingart DE, Doherty GM, Gaucer PG, et al, 2005 Management of patients with adrenal cancer: recomendations of an international consensus conference. Endoc Relat Cancer 12: 667–680.
Terzolo M, Angeli A, Fassnacht M, et al, 2007 Adgiuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356: 2372–2380.
Hahner S, Fassnacht M, 2005 Mitotane for adrenal carcinoma treatment. Curr Opin Investig Drugs 6: 386–394.
Young RB, Bryson MJ, Sweat ML, Street JC, 1973 Complexing of DDT and o,p’DDD with adrenal cyto-chrome P-450 hydroxylating systems. J Steroid Biochem 4: 585–591.
Trainer PJ, Besser M, 1994 Cushing’s syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am 23: 571–584.
Løvås K, Curran S, Øksnes M, et al, 2010 Development of a disease-specific quality of life questionnaire in Addison’s disease. J Clin Endocrinol Metab 95: 545–551.
Lacroix A, 2010 Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab 95: 4812–4822.
Bledsoe T, Island DP, Ney RL, Liddle GW, 1964 An effect of o,p-DDD on the extra-adrenal metabolism of cortisol in man. J Clin Endocrinol Metab 24: 1303–1311.
Van Seters AP, Moolenaar AJ, 1991 Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinolol (Copenh) 124: 526–533.
Gröschl M, 2008 Current status of salivary hormone analysis. Clin Chem 54: 1759–1769.
Daffara F, De Francia S, Reimondo G, et al, 2008 Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15: 1043–1053.
Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ, Keevil BG, 2009 Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. J Chromatogr B Anal yt Technol Biomed Life Sci 877: 3771–3775.
Matsui F, Koh E, Yamamoto K, et al, 2009 Liquid chromatography-tandem mass spectrometry (LC-MS/ MS) assay for simultaneous measurement of salivary testosterone and cortisol in healthy men for utilization in the diagnosis of late-onset hypogonadism in males. Endocr J 56: 1083–1093.
Jönsson BA, Malmberg B, Amilon A, Helene Garde A, Orbaek P, 2003 Determination of cortisol in human saliva using liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 784: 63–68.
Owen LJ, Haslam S, Adaway JE, Wood P, Glenn C, Keevil BG, 2010 A simplified liquid chromatography tandem mass spectrometry assay, using on-line solid-phase extraction, for the quantitation of cortisol in saliva and comparison with a routine DELFIA method. Ann Clin Biochem 47: 131–136.
Persichilli S, Gervasoni J, Iavarone F, Zuppi C, 2010 A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose. Clin Chem Lab Med 48: 1433–1437.
Allolio B, Fassnacht M, 2006 Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91: 2027–2037.
Nieman LK, Biller BM, Findling JW, et al, 2008 The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93: 1526–1540.
Carrozza C, Corsello SM, Paragliola RM, et al, 2010 Clinical accuracy of midnight salivarycortisol measured by automated electrochemiluminescence immunoassay method in Cushing’s syndrome. Ann Clin Biochem 47: 228–232.
Raff H, Homar PJ, Burns EA, 2002 Comparison of two methods for measuring salivary cortisol. Clin Chem 48: 207–208.
Vogeser M, Durner J, Seliger E, Auernhammer C, 2006 Measurement of late-night salivary cortisol with an automated immunoassay system. Clin Chem Lab Med 44: 1441–1445.
Van Aken MO, Romijn JA, Miltenburg JA, Lentjes EG, 2003 Automated measurement of salivary cortisol. Clin Chem 49: 1408–1409.
Pearson Murphy BE, 1999 Lack of specificity of urinary free cortisol determinations: why does it continue? J Clin Endocrinol Metab 84: 2258–2259.
Putignano P, Kaltsas GA, Satta MA, Grossman AB, 1998 The effects of anti-convulsant drugs on adrenal function. Horm Metab Res. 30: 389–397.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carrozza, C., Lapolla, R., Gervasoni, J. et al. Assessment of salivary free cortisol levels by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in patients treated with mitotane. Hormones 11, 344–349 (2012). https://doi.org/10.14310/horm.2002.1363
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1363